CD79A and Familial prostate cancer: The novel FRLRS prognostic signature regulated could be found in tumor and immune-related pathways, including cytokine-receptor interaction, glycerophospholipid metabolism, homologous recombination, IgA production, primary immunodeficiency, endometrial cancer, peroxisome, propanoate metabolism, prostate cancer, valine leucine, and isoleucine degradation (Supplementary Table S6).